HomeEvolutionMatTek and AIM Biotech Accomplice on Superior 3D Tissue Tradition Organ-on-a-Chip Programs

MatTek and AIM Biotech Accomplice on Superior 3D Tissue Tradition Organ-on-a-Chip Programs

As we speak, MatTek Life Sciences and AIM Biotech introduced a strategic partnership by which the AIM Biotech portfolio will likely be out there on the market by MatTek. Over the past thirty years, MatTek has turn out to be the chief within the superior cell tradition house and is regularly working to broaden its portfolio of services. The partnership with AIM Biotech permits MatTek to supply an ever extra complete suite of services to its shoppers and prospects.

This contains the revolutionary organiX™ and idenTX™ microfluidic 3D tissue tradition platforms in addition to complete drug discovery analysis providers in key therapeutic areas of immuno-oncology, vascular biology, and neurobiology.

Whereas MatTek has led the sphere in superior cell tradition and tissue tradition for many years with fashions corresponding to EpiDerm™, and most just lately EpiKidney™, these fashions have been developed as a single organ system inside an in vitro format. As researchers push the envelope on superior in vitro programs, they’re changing into extra desirous about fashions which incorporate much more physiologically related options, corresponding to perfusable vasculature, and even combining a number of organ programs.

One in all our targets is to proceed to reinforce the complexity of in vitro tissue know-how and preserve bringing it nearer and nearer to in vivo human biology, and the microfluidic cell tradition platforms from AIM Biotech can just do that,” stated MatTek CEO Alex Armento. “By partnering with AIM Biotech we will extra simply add perfusable vasculature to in vitro fashions and construct ever extra physiologically related assays which assist higher predict in vivo outcomes.”

“AIM Biotech is happy to companion with MatTek with the intention to get our superior 3D tissue tradition platforms in addition to our in depth portfolio of application-specific steerage and providers into the palms of extra researchers from all over the world. Collectively we’re taking the initiative to mix AIM Biotech’s means to create self-assembling, immunocompetent, perfusable programs with MatTek’s extensively validated cell tradition fashions. It will allow us to advance the event of assay-ready programs that are simpler to make use of and can present physiological information earlier within the drug improvement course of,” described AIM Biotech CEO Jim McGorry.

AIM Biotech’s Organ-on-a-Chip Tissue Tradition Platforms at the moment are out there on the market on MatTek’s on-line retailer.

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments